Wegovy tablets contain semaglutide, a GLP-1 receptor agonist that has been extensively studied for weight management in adults living with obesity or overweight with weight-related health conditions.
The UK approval of Wegovy tablets was based on the phase 3 OASIS 4 clinical trial, which evaluated once-daily oral semaglutide 25 mg alongside diet and lifestyle changes in adults without diabetes.
In the OASIS 4 study, participants receiving oral semaglutide achieved an average weight loss of approximately 14% after 64 weeks when analysed regardless of treatment adherence. Among participants who remained on treatment as intended, average weight loss reached approximately 16.6%.
Importantly, around one-third of participants achieved at least 20% weight loss, demonstrating the potential for clinically meaningful weight reduction in suitable patients.
The study also demonstrated improvements in several cardiometabolic risk factors, including waist circumference, blood pressure and markers of metabolic health.
Wegovy tablets are designed to be used alongside a reduced-calorie diet, increased physical activity and ongoing clinical support. At Pharmulous, all treatment recommendations are made following an individual clinical assessment by our healthcare team.
Wegovy tablets contain semaglutide, a GLP-1 receptor agonist used to support weight management. The tablets are taken once daily and provide a needle-free alternative to injectable GLP-1 treatments.
Who may be suitable for Wegovy tablets?
Wegovy tablets may be suitable for eligible adults seeking weight loss or long-term weight maintenance. A clinical assessment is required before treatment can be prescribed.
How do I take Wegovy tablets?
Wegovy tablets are taken once daily with a small amount of water, following the instructions provided by your prescriber.
What strengths are available?
Wegovy tablets are available in multiple strengths.
Treatment is usually started at a lower strength before gradually increasing to the maintenance dose.
Your prescriber will advise the most appropriate dose based on your treatment plan.
Wegovy tablets are available in four strengths:
✓ 1.5mg
✓ 4mg
✓ 9mg
✓ 25mg
Treatment typically starts at a lower dose and gradually increases before reaching the maintenance dose.
What is the dose escalation schedule?
Most patients follow this progression:
✓ Month 1: 1.5mg once daily
✓ Month 2: 4mg once daily
✓ Month 3: 9mg once daily
✓ Month 4 onwards: 25mg once daily
Your prescriber may adjust treatment based on your individual needs.
Can I switch from Wegovy injections?
Some patients may be eligible to transition from Wegovy injections to Wegovy tablets. Your clinician will determine whether switching is appropriate.
Can I switch from Mounjaro to Wegovy tablets?
Patients currently using Mounjaro may be able to switch to Wegovy tablets following a clinical review and personalised treatment plan.
Can Wegovy tablets help maintain weight loss?
Yes. Wegovy tablets can be prescribed for patients who have achieved their target weight and wish to maintain their results with ongoing clinical support.
What side effects can occur?
Common side effects may include:
Nausea
Constipation
Diarrhoea
Stomach discomfort
Reduced appetite
These effects are often temporary and may improve as treatment progresses.
How can I buy Wegovy tablets?
Complete the Pharmulous online assessment and a qualified prescriber will review whether Wegovy tablets are suitable for your weight management goals.
Sign up to our newsletter
Sign up to be the first to know about promotions and news.
